Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers13071513
DC FieldValue
dc.titleDysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention
dc.contributor.authorFhu, Chee Wai
dc.contributor.authorAli, Azhar
dc.date.accessioned2022-06-07T09:12:41Z
dc.date.available2022-06-07T09:12:41Z
dc.date.issued2021-04-01
dc.identifier.citationFhu, Chee Wai, Ali, Azhar (2021-04-01). Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention. CANCERS 13 (7). ScholarBank@NUS Repository. https://doi.org/10.3390/cancers13071513
dc.identifier.issn2072-6694
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/226659
dc.description.abstractThe ubiquitin proteasome system (UPS) governs the non-lysosomal degradation of oxi-dized, damaged, or misfolded proteins in eukaryotic cells. This process is tightly regulated through the activation and transfer of polyubiquitin chains to target proteins which are then recognized and degraded by the 26S proteasome complex. The role of UPS is crucial in regulating protein levels through degradation to maintain fundamental cellular processes such as growth, division, signal transduction, and stress response. Dysregulation of the UPS, resulting in loss of ability to maintain protein quality through proteolysis, is closely related to the development of various malignancies and tumorigenesis. Here, we provide a comprehensive general overview on the regulation and roles of UPS and discuss functional links of dysregulated UPS in human malignancies. Inhibitors developed against components of the UPS, which include U.S. Food and Drug Administration FDA-approved and those currently undergoing clinical trials, are also presented in this review.
dc.language.isoen
dc.publisherMDPI
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.subjectubiquitin proteasome system
dc.subjectdysregulation
dc.subjectchemoresistance
dc.subjectcancer
dc.subjecttherapy
dc.subjectinhibitors
dc.typeReview
dc.date.updated2022-06-07T01:35:30Z
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.3390/cancers13071513
dc.description.sourcetitleCANCERS
dc.description.volume13
dc.description.issue7
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2021Cancers-13-01513.pdf785.54 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.